MedTrace Logo

CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation

NCT04558333 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-05-03

No results posted yet for this study

Summary

Lung transplantation is the ultimate treatment for end stage lung diseases. Survival after lung transplantation is limited mainly due to the development of chronic allograft dysfunction (CLAD). Both acute cellular rejection and primary grade dysfunction (PGD) have been associated with the development of CLAD. In this study we will investigate multiple prognostic factors that influence long term survival after lung transplantation with a specific interest in PGD, acute rejection and the development of CLAD.

Conditions

  • Lung Transplant Failure and Rejection
  • Primary Graft Dysfunction

Interventions

OTHER

blood and exhaled breath specimens

identification of possible biomarkers

Sponsors & Collaborators

  • University Hospital, Antwerp

    lead OTHER

Principal Investigators

  • Thérèse Lapperre, MD · University Hospital, Antwerp

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2024-02-28
Completion
2024-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04558333 on ClinicalTrials.gov